Neuberger Berman Group LLC lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 5.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 827,730 shares of the medical research company’s stock after selling 48,903 shares during the period. Neuberger Berman Group LLC owned 1.74% of Charles River Laboratories International worth $83,725,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Karp Capital Management Corp acquired a new stake in shares of Charles River Laboratories International during the first quarter worth approximately $1,994,000. UBS Asset Management Americas Inc. raised its stake in shares of Charles River Laboratories International by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 89,008 shares of the medical research company’s stock worth $8,006,000 after buying an additional 228 shares during the period. Swiss National Bank raised its stake in shares of Charles River Laboratories International by 0.6% in the first quarter. Swiss National Bank now owns 78,300 shares of the medical research company’s stock worth $7,043,000 after buying an additional 500 shares during the period. Comerica Bank raised its stake in shares of Charles River Laboratories International by 5.1% in the first quarter. Comerica Bank now owns 36,844 shares of the medical research company’s stock worth $3,302,000 after buying an additional 1,803 shares during the period. Finally, Suntrust Banks Inc. raised its stake in shares of Charles River Laboratories International by 15.8% in the first quarter. Suntrust Banks Inc. now owns 6,624 shares of the medical research company’s stock worth $594,000 after buying an additional 904 shares during the period. Institutional investors and hedge funds own 95.82% of the company’s stock.

Shares of Charles River Laboratories International, Inc. (CRL) opened at 106.80 on Thursday. The company has a market capitalization of $5.08 billion, a price-to-earnings ratio of 28.14 and a beta of 1.02. The firm has a 50 day moving average price of $100.04 and a 200 day moving average price of $93.17. Charles River Laboratories International, Inc. has a 52 week low of $67.20 and a 52 week high of $107.39.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. During the same period in the prior year, the company earned $1.20 earnings per share. The firm’s revenue was up 8.1% on a year-over-year basis. Equities analysts forecast that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has authorized a share repurchase program on Wednesday, May 10th that permits the company to repurchase $150.00 million in shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/31/charles-river-laboratories-international-inc-crl-stake-cut-by-neuberger-berman-group-llc.html.

A number of brokerages recently commented on CRL. Jefferies Group LLC reiterated a “buy” rating and set a $121.00 price target on shares of Charles River Laboratories International in a report on Friday, June 30th. BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 22nd. Zacks Investment Research lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Citigroup Inc. restated a “neutral” rating and issued a $104.00 target price (up from $91.00) on shares of Charles River Laboratories International in a research note on Wednesday, June 28th. Finally, Barclays PLC restated a “hold” rating and issued a $102.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Charles River Laboratories International presently has a consensus rating of “Hold” and an average price target of $96.94.

In other Charles River Laboratories International news, insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the transaction, the insider now owns 11,671 shares in the company, valued at $783,124.10. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider William D. Barbo sold 4,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $99.91, for a total transaction of $399,640.00. Following the completion of the transaction, the insider now owns 20,424 shares of the company’s stock, valued at approximately $2,040,561.84. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 74,945 shares of company stock worth $7,398,279. 2.20% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.